SCHEMBL30493103

SCHEMBL30493103

Nc1ccc2cnnc(N)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 2/20 0.41
MAOA P21397 2/20 0.41
PTGS1 P23219 2/20 0.41
F2 P00734 1/20 0.41
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
DRD1 P21728 1/20 0.41
ACHE P22303 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
OPRM1 P35372 1/20 0.41
DRD3 P35462 1/20 0.41
KDR P35968 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8214263 0.82 C1S (0.51) MEN1KMT2ALMNAACHEC1S
SCHEMBL22715522 0.82 MEN1 (0.45) MEN1KMT2AHTTACHEC1S
SCHEMBL2054649 0.77 LRRK2 (0.40) MEN1KMT2AKCNH2HRH3C1S
SCHEMBL4767037 0.77 C1S (0.52) MEN1KMT2AACHEC1SMAPT
SCHEMBL2056363 0.77 TYMS (0.41) MEN1KMT2AHTTLMNAC1S
SCHEMBL23869922 0.77 NPC1 (0.39) MEN1KMT2AHTTLMNAC1S
SCHEMBL29560277 0.76 KDM4E (0.57) KMT2ALMNAMAOAPTGS1KDR
SCHEMBL600018 0.76 KDM4E (0.57) KMT2ALMNAMAOAPTGS1KDR
SCHEMBL27603097 0.75 PLAU (0.36) MEN1KMT2AHTTLMNAMAOA
Hydrochloric Acid SCHEMBL27687770 0.74 KDM4E (0.58) KMT2ALMNAMAOAPTGS1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-20230137886-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 MEN1 214/4885KMT2A 3283/4885HTT 4369/4885
US-20230137886-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 MEN1 214/4885KMT2A 3283/4885HTT 4369/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 MEN1 214/4885KMT2A 3283/4885HTT 4369/4885
US-11702418-B2 SOS1 inhibitors SOS1, SOS2, SOST MEN1 184/4885KMT2A 3302/4885HTT 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.